Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19138894 | 1.00 | HDAC6 (0.74) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL19161578 | 0.94 | HDAC6 (0.74) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL17500279 | 0.94 | HDAC6 (0.74) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL19161577 | 0.89 | HDAC6 (0.71) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL19138896 | 0.89 | HDAC6 (0.71) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL17520584 | 0.88 | HDAC6 (0.65) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL19138953 | 0.88 | HDAC6 (0.64) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL19138924 | 0.88 | HDAC6 (0.72) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL19139013 | 0.87 | HDAC6 (0.56) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL19138918 | 0.87 | HDAC6 (0.66) | HDAC6HDAC2HDAC8HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177621-B1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | UNIV REGENSBURG (DE) | 2021-11-10 | — | — | EP | disclosed |
| US-20170210743-A1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | Universitätsklinikum Jena (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210743-A1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | Universitätsklinikum Jena (DE) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210743-A1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | HDAC6, HDAC5, HDAC4 | HDAC6 1/4885HDAC2 6/4885HDAC8 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.